RPH approves trials of cardiac device

Royal Perth Hospital had granted ethics approval to NSW-based cardiac device development company Sunshine Heart Inc for a trial program of its C-Pulse device.

The clinical trial will investigate the safety of the C-Pulse and its ability to improve the heart function of patients with heart failure by increasing blood supply to the heart muscle and reducing the hearts pumping work. The C-Pulse is designed as a non-blood contacting heart-assist device, reducing the risks of bleeding complications and making it safe to turn the device on and off.

The full announcement from Sunshine is pasted below

Sunshine Heart, Inc. announced today that it has received ethics approval to commence its C-PulseTM clinical trial program at Royal Perth Hospital in Western Australia.

Royal Perth Hospital joins Auckland City Hospital in New Zealand, the Alfred Hospital and Southern Health Monash Medical Centre in Melbourne and St Vincents Hospital in Sydney in Australia in the multi-centre pilot clinical trial of the C-PulseTM.

The clinical trial will investigate the safety of the C-Pulse and its ability to improve the heart function of patients with heart failure by increasing blood supply to the heart muscle and reducing the hearts pumping work. The C-Pulse is uniquely designed as a non-blood contacting heart-assist device, reducing the risks of bleeding complications and making it safe to turn the device on and off.